Genmab A/S (GMAB) News Today

Genmab A/S (NASDAQ:GMAB - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twelve analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and eigh

SG Americas Securities LLC boosted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 360.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,500 shares of the company's stock after purcha

HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday.

QRG Capital Management Inc. trimmed its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 48.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,519 shares of the company's stock after selling 34,633 shares during the qua

Williams Jones Wealth Management LLC. cut its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 40.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,435 shares of the company's stock after selling 60,702 sha

Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday.

Genmab A/S (NASDAQ:GMAB) Sets New 1-Year Low at $24.94

Goldman Sachs Group Inc. trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 17.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 527,924 shares of the company's stock after se

Genmab A/S (NASDAQ:GMAB - Get Free Report) has been assigned an average rating of "Hold" from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a

BTIG Research lifted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday.

HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday.

Wellington Management Group LLP cut its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,369,331 shares of the company's stock after selling 5

Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase

Genmab A/S (NASDAQ:GMAB) Sets New 1-Year Low at $26.32

Harding Loevner LP boosted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,289,895 shares of the company's stock after acquiring an additional 85,665 share

Royal London Asset Management Ltd. cut its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 91.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,706 shares of the company's stock after sellin

First Trust Advisors LP grew its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 16.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,270,095 shares of the company's stock after purchasing an additional 175,292 shares du

Capital International Investors trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,057,922 shares of the company's stock after selling 2

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 2,960,000 shares, an increase of 7.6% from the April 30th total of 2,750,000 shares. Based on an average daily volume of 520,800 shares, the days-to-cover ratio is presently 5.7 days. Currently, 0.5% of the company's shares are sold short.

Campbell & CO Investment Adviser LLC bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 59,003 shares of the company's stock, valued at approxima

HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Monday.

Wells Fargo & Company MN trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 557,132 shares of the company's stock after selling 32,261 shares during the

Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.34